No Data
Hong Kong stocks movement | Most pharmaceutical stocks rebounded in the morning, REMEGEN (09995) rose over 8%, and HeYu-B (02256) rose nearly 7%.
Most pharmaceutical stocks rebounded in the early trading session. As of the time of reporting, REMEGEN (09995) rose by 8.14% to 40.5 HKD; HEYU-B (02256) increased by 6.71% to 7.79 HKD; BEIGENE (06160) went up by 5.24% to 134.4 HKD.
Pharmaceutical stocks are under significant pressure. 3SBIO (01530) falls by 7.95% as Trump plans to immediately reduce drug prices by 30%-80%.
Jinwu Financial News | Pharmaceutical stocks are under significant pressure, with 3SBIO (01530) down 7.95%, KEYMED BIO-B (02162) down 6.42%, ASCENTAGE-B (06855) down 7.05%, ZAI LAB (09688) down 6.78%, BEIGENE (06160) down 6.20%, Lepu Bio-B (02157) down 5.12%, CSPC PHARMA (01093) down 5.92%, INNOVENT BIO (01801) down 5.25%, and AKESO (09926) down 4.45%. The President of the USA, Trump, stated that an executive order will be signed at the White House.
From PD-1 to several leading ADCs, Lepu Biotech-B (02157) is facing a value re-evaluation.
The stock price has increased by nearly 78% this year, has Lepu Biopharma captured investors' hearts with its ADC drugs?
LEPU BIO-B: 2024 Annual Report
The Medical sector has frequently issued Bullish policies, leading to a significant increase in the Hang Seng Yinhua CSI Innovative Drugs Industry ETF, Hang Seng Biotechnology ETF, Hang Seng Medical Index ETF, and Hong Kong Stock Connect Medical ETF.
Innovative Drugs and Medical stocks in Hong Kong surged, with INNOCARE, SIMCERE PHARMA, and ASCENTAGE-B rising over 12%; Lepu Biopharma-B, CMS, CSPC PHARMA, INNOVENT BIO, and Hutchmed (China) increased by more than 7%.
Lepu Biopharma Co., Ltd.'s (HKG:2157) Shares Climb 29% But Its Business Is Yet to Catch Up
